Gentium S.p.A.

Gentium Announces Presentation of Defibrotide Clinical Data at the American Society of Hematology Annual Meeting.(Conference news)
Business Wire; 11/16/2009; 1105 words; ...VILLA GUARDIA (COMO), Italy -- Gentium S.p.A. (Nasdaq: GENT) announced today that results from the Company's Phase II/III Pediatric Prevention...Morial Convention Center, Room 350. Gentium S.p.A., located in Como, Italy...

Gentium Announces New Board of Directors and Interim CEO.
Business Wire; 11/9/2009; 1248 words; ...VILLA GUARDIA (COMO), Italy -- Gentium S.p.A. (Nasdaq: GENT) announced...and Chief Executive Officer of Gentium S.p.A., previous Chairperson of...and media section. About Gentium Gentium S.p.A., located in Como, Italy...

Gentium Reports Second Quarter Financial Results; Provides Financial and Clinical Update.(Financial report)
Business Wire; 9/17/2009; 2539 words; ...VILLA GUARDIA (COMO), Italy -- Gentium S.p.A. (NASDAQ: GENT) today reported...30, 2009. Financial Highlights Gentium S.p.A., or the Company, reports...and Chief Financial Officer of Gentium S.p.A. "We believe that the results...

Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease.
Pediatrics Week; 9/5/2009; 1193 words; Gentium S.p.A. (NASDAQ: GENT) announced top...of the Dana-Farber Cancer Institute's Jerome Lipper Multiple Myeloma Center and...Treatment, Veno-occlusive Disease, Gentium S.p.A. This article was prepared by Pediatrics...

News and FDA Updates for Am Scien Res (OTC:ASFX), Gentium (NASDAQ:GENT), Bio-Matrix (OTC:BMSN), Entest BioMed(OTC:ENTB).
M2 Presswire; 8/20/2009; 971 words; ...for Am Scien Res (OTC:ASFX), Gentium (NASDAQ:GENT), Bio-Matrix...portal which covers Wall Street's biomedical sector and delivers financial...Disintegrator Plus(TM). On 08/19/09, Gentium S.p.A. (NASDAQ:GENT), announced...